RxDoctor Payments DataLook up a doctor →

Vishnu Reddy, MD

Gastroenterology · Ocala, FLNPI 1184617938

Payments from drug & device makers

$677,018in general payments, 2019–2025

Across 461 payments — averaging $1468.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$485K
  • Bausch Health US, LLC$140K
  • AbbVie$42K
  • Pfizer$8K
  • Phathom Pharmaceuticals, Inc.$385
  • Boston Scientific$220
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,81798%
  • Education$592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$677,018 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$221,397
Medicare patients
302
Services billed
3,014

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase65$241,535
LinzessLinaclotide128$126,482
ZenpepLipase/Protease/Amylase20$65,459
TrulancePlecanatide22$28,005
Famotidine1,205$22,292
VoqueznaVonoprazan Fumarate20$20,201
Sucralfate739$16,459
Pantoprazole Sodium1,011$8,826
Dexlansoprazole DrDexlansoprazole32$7,129
CarafateSucralfate13$5,894
Omeprazole405$5,328
Ondansetron OdtOndansetron55$2,415
Esomeprazole Magnesium38$1,911
Dicyclomine Hcl40$1,140
Azithromycin45$913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$41,708$368,018193 claims
Aimmune Therapeutics, Inc.Zenpep$14$65,45920 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$205$28,00522 claims
Phathom Pharmaceuticals, Inc.Voquezna$385$20,20120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →